Shuttle Pharmaceuticals Holdings IncNASDAQ SHPH Stock Report

Shuttle Pharmaceuticals Holdings, Inc. engages in the development of novel therapies for cancer. The company is headquartered in Rockville, Maryland and currently employs 4 full-time employees. The company went IPO on 2022-08-31. The company is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). The firm by developing radiation sensitizers helps to increase cancer cure rates, prolong patient survival and improve quality of life when used as a primary treatment, or in combination with surgery, chemotherapy and immunotherapy. The company is engaged in developing a clinical-stage product candidate (Ropidoxuridine) and selective histone deacetylase (HDAC6) inhibitor (SP-2-225). Its platform of sensitizers offers a pipeline of product candidates designed to address the urgent clinical need and the current limitations of using off-label drugs with potential new sensitizer agents. Ropidoxuridine is a clinical sensitizer drug candidate, to sensitize rapidly growing cancer cells, and selective HDAC inhibitors to sensitize cancer cells and stimulate the immune system.